Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial.
Saved in:
| Title: | Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial. |
|---|---|
| Authors: | Kandel C; Michael Garron Hospital, Toronto, Canada. Electronic address: christopher.kandel@tehn.ca., Biondi MJ; York University, Toronto, Canada; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Gillrie M; University of Calgary, Cumming School of Medicine, Calgary, Canada., Taylor M; Michael Garron Hospital, Toronto, Canada., Barber B; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Amiri L; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Robinson T; University of Calgary, Cumming School of Medicine, Calgary, Canada., Powis J; Michael Garron Hospital, Toronto, Canada., Adhikari NK; Department of Critical Care Medicine, Sunnybrook Health Science Centre, Toronto, Canada; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada., Kozak RA; Sunnybrook Health Science Centre, Toronto, Canada., Zahoor MA; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Smookler D; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Booth J; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Jeganathan S; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Stanislau E; Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo and Inspirali, São Paulo, Brazil., Gehring AJ; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Hirode G; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Noureldin S; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Capraru C; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada., Hansen B; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada; Erasmus University, Rotterdam, The Netherlands., Feld JJ; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada. |
| Source: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2025 Dec; Vol. 31 (12), pp. 2048-2055. Date of Electronic Publication: 2025 Aug 14. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9516420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-0691 (Electronic) Linking ISSN: 1198743X NLM ISO Abbreviation: Clin Microbiol Infect Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40818744 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kandel+C%22">Kandel C</searchLink>; Michael Garron Hospital, Toronto, Canada. Electronic address: christopher.kandel@tehn.ca.<br /><searchLink fieldCode="AU" term="%22Biondi+MJ%22">Biondi MJ</searchLink>; York University, Toronto, Canada; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Gillrie+M%22">Gillrie M</searchLink>; University of Calgary, Cumming School of Medicine, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Taylor+M%22">Taylor M</searchLink>; Michael Garron Hospital, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Barber+B%22">Barber B</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Amiri+L%22">Amiri L</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Robinson+T%22">Robinson T</searchLink>; University of Calgary, Cumming School of Medicine, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Powis+J%22">Powis J</searchLink>; Michael Garron Hospital, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Adhikari+NK%22">Adhikari NK</searchLink>; Department of Critical Care Medicine, Sunnybrook Health Science Centre, Toronto, Canada; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Kozak+RA%22">Kozak RA</searchLink>; Sunnybrook Health Science Centre, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Zahoor+MA%22">Zahoor MA</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Smookler+D%22">Smookler D</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Booth+J%22">Booth J</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Jeganathan+S%22">Jeganathan S</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Stanislau+E%22">Stanislau E</searchLink>; Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo and Inspirali, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Gehring+AJ%22">Gehring AJ</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Hirode+G%22">Hirode G</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Noureldin+S%22">Noureldin S</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Capraru+C%22">Capraru C</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Hansen+B%22">Hansen B</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada; Erasmus University, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Feld+JJ%22">Feld JJ</searchLink>; Toronto Centre for Liver Disease, University Health Network, Toronto, Canada. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229516420%22">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</searchLink> [Clin Microbiol Infect] 2025 Dec; Vol. 31 (12), pp. 2048-2055. <i>Date of Electronic Publication: </i>2025 Aug 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9516420 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1469-0691 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221198743X%22">1198743X </searchLink><i>NLM ISO Abbreviation: </i>Clin Microbiol Infect <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40818744 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.cmi.2025.08.003 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2048 Titles: – TitleFull: Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kandel C – PersonEntity: Name: NameFull: Biondi MJ – PersonEntity: Name: NameFull: Gillrie M – PersonEntity: Name: NameFull: Taylor M – PersonEntity: Name: NameFull: Barber B – PersonEntity: Name: NameFull: Amiri L – PersonEntity: Name: NameFull: Robinson T – PersonEntity: Name: NameFull: Powis J – PersonEntity: Name: NameFull: Adhikari NK – PersonEntity: Name: NameFull: Kozak RA – PersonEntity: Name: NameFull: Zahoor MA – PersonEntity: Name: NameFull: Smookler D – PersonEntity: Name: NameFull: Booth J – PersonEntity: Name: NameFull: Jeganathan S – PersonEntity: Name: NameFull: Stanislau E – PersonEntity: Name: NameFull: Gehring AJ – PersonEntity: Name: NameFull: Hirode G – PersonEntity: Name: NameFull: Noureldin S – PersonEntity: Name: NameFull: Capraru C – PersonEntity: Name: NameFull: Hansen B – PersonEntity: Name: NameFull: Feld JJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2025 Dec Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1469-0691 Numbering: – Type: volume Value: 31 – Type: issue Value: 12 Titles: – TitleFull: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Type: main |
| ResultId | 1 |